Recently Added Drugs
1. Abilify Maintena Kit patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12691056 | OTSUKA | NA |
Apr, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 28, 2016 |
| M(M-150) | Dec 05, 2017 |
| New Indication(I-746) | Jul 27, 2020 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 28 February, 2013
Treatment: Maintenance monotherapy treatment of bipolar i disorder
Dosage: FOR SUSPENSION, EXTENDED RELEASE
How can I launch a generic of ABILIFY MAINTENA KIT before its drug patent expiration?
More Information on Dosage
ABILIFY MAINTENA KIT family patents
2. Axtle patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12721811 | AVYXA | NA |
Jun, 2045
(18 years from now) | |
Drugs and Companies using PEMETREXED DIPOTASSIUM ingredient
Market Authorisation Date: 28 June, 2024
Treatment: NA
Dosage: POWDER
More Information on Dosage
AXTLE family patents
3. Bondlido patent
expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8722065 | MEDRX | Lidocaine Tape Preparation |
Nov, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 24, 2028 |
Drugs and Companies using LIDOCAINE ingredient
Market Authorisation Date: 24 September, 2025
Treatment: NA
Dosage: SYSTEM
More Information on Dosage
BONDLIDO family patents
4. Contepo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12702676 | MEITHEAL | NA |
Jan, 2039
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 22, 2028 |
| Generating Antibiotic Incentives Now(GAIN) | Oct 22, 2033 |
Drugs and Companies using FOSFOMYCIN DISODIUM ingredient
Market Authorisation Date: 22 October, 2025
Treatment: Treatment of renally impaired patients with complicated urinary tract infections including acute pyelonephritis caused by susceptible isolates of escherichia coli and klebsiella pneumoniae
Dosage: POWDER
More Information on Dosage
CONTEPO family patents
5. Duloxetine Hydrochloride patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12721817 | ALMATICA | NA |
Jan, 2046
(19 years from now) | |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 27 February, 2026
Treatment: NA
Dosage: CAPSULE, DELAYED REL PELLETS
More Information on Dosage
DULOXETINE HYDROCHLORIDE family patents
6. Elucirem patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12064487 | GUERBET | Complex Of Gadolinium And A Chelating Ligand Derived From A Diastereoisomerically Enriched Pcta And Preparation And Purification Process |
Jan, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 21, 2027 |
| New Patient Population(NPP) | Feb 20, 2029 |
Drugs and Companies using GADOPICLENOL ingredient
NCE-1 date: 21 September, 2026
Market Authorisation Date: 21 September, 2022
Treatment: Method of magnetic resonance imaging to detect and visualize lesions with abnormal vascularity in the central nervous system (brain, spine, and associated tissues) and the body (head and neck, thorax,...
Dosage: SOLUTION
More Information on Dosage
ELUCIREM family patents
7. Furoscix Readyflow (autoinjector) patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11497755 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide |
Jan, 2040
(13 years from now) | |
| US11559535 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide |
Jan, 2040
(13 years from now) | |
| US11571434 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide |
Jan, 2040
(13 years from now) | |
| US11998555 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | |
| US12048709 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | |
| US12491193 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | |
| US12491194 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | |
| US12491195 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | |
| US12491196 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | |
| US12491197 | SCPHARMACEUTICALS | Concentrated Liquid Pharmaceutical Formulations Of Furosemide And Methods Of Administering The Same |
Jan, 2040
(13 years from now) | |
Drugs and Companies using FUROSEMIDE ingredient
Market Authorisation Date: 07 October, 2022
Treatment: Use for the treatment of edema in a patients with chronic heart failure or chronic kidney disease; Use for the treatment of edema in patients with chronic heart failure or chronic kidney disease
Dosage: SOLUTION
More Information on Dosage
FUROSCIX READYFLOW (AUTOINJECTOR) family patents
8. Gavreto patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12692251 | RIGEL | Pralsetinib Pharmaceutical Compositions |
Apr, 2043
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Sep 04, 2025 |
| Orphan Drug Exclusivity(ODE-318) | Sep 04, 2027 |
| Orphan Drug Exclusivity(ODE-340) | Dec 01, 2027 |
| Orphan Drug Exclusivity(ODE-341) | Dec 01, 2027 |
Drugs and Companies using PRALSETINIB ingredient
NCE-1 date: 04 September, 2024
Market Authorisation Date: 04 September, 2020
Treatment: NA
Dosage: CAPSULE
More Information on Dosage
GAVRETO family patents
9. Gomekli patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11066358 | SPRINGWORKS | Compositions of essentially pure form IV of N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(14 years from now) | |
| US11084780 | SPRINGWORKS | Door construction |
Feb, 2041
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11453641 | SPRINGWORKS | Methods of treating neurofibromatosis with N-((R)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
Feb, 2041
(14 years from now) | |
| US11571402 | SPRINGWORKS | Dispersible formulations of N-((R)-2,3-dihydroxypropoly)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and uses thereof |
Feb, 2041
(14 years from now) | |
| US11806321 | SPRINGWORKS | Non-linear dosing of mirdametinib |
Feb, 2041
(14 years from now) | |
| US11819487 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(14 years from now) | |
| US12037306 | SPRINGWORKS | Methods of treating neurofibromatosis type 1 with N-((R))-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
Feb, 2041
(14 years from now) | |
| US12263146 | SPRINGWORKS | Non-linear dosing of mirdametinib |
Feb, 2041
(14 years from now) | |
| US12295925 | SPRINGWORKS | Treatment of neurofibromatosis type 1 (NF1) associated plexiform neurofibromas (PN) in pediatric patients with mirdametinib |
Feb, 2041
(14 years from now) | |
| US12357597 | SPRINGWORKS | Dispersible Formulations Of N-((R)-2,3-Dihydroxypropoxy)-3,4-Difluoro-2-(2-Fluoro-4-Iodo-Phenylamino)-Benazmide And Uses Thereof |
Feb, 2041
(14 years from now) | |
| US11883375 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(16 years from now) | |
| US12220390 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(16 years from now) | |
| US12257215 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(16 years from now) | |
| US12324791 | SPRINGWORKS | Mirdametinib treatment |
Mar, 2043
(16 years from now) | |
| US12661330 | SPRINGWORKS | Mirdametinib Treatment |
Feb, 2044
(17 years from now) | |
| US12029711 | SPRINGWORKS | Dosage forms of mirdametinib |
Mar, 2044
(17 years from now) | |
| US12390430 | SPRINGWORKS | NA |
Oct, 2044
(18 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 11, 2030 |
| ODE*(ODE*) | Feb 11, 2032 |
| Orphan Drug Exclusivity(ODE-488) | Feb 11, 2032 |
Drugs and Companies using MIRDAMETINIB ingredient
NCE-1 date: 11 February, 2029
Market Authorisation Date: 11 February, 2025
Treatment: Treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic plexiform neurofibromas (pn) not amenable to complete resection; Treatment o...
Dosage: TABLET, FOR SUSPENSION
More Information on Dosage
GOMEKLI family patents
10. Inqovi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12697347 | TAIHO | NA |
Dec, 2042
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 07, 2025 |
| Orphan Drug Exclusivity(ODE-316) | Jul 07, 2027 |
| New Indication(I-990) | May 13, 2029 |
Drugs and Companies using CEDAZURIDINE; DECITABINE ingredient
NCE-1 date: 07 July, 2024
Market Authorisation Date: 07 July, 2020
Treatment: Treatment in combination with venetoclax of newly-diagnosed acute myeloid leukemia (aml) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy
Dosage: TABLET
More Information on Dosage
INQOVI family patents
11. Katerzia patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12721843 | AZURITY | NA |
Oct, 2037
(11 years from now) | |
Drugs and Companies using AMLODIPINE BENZOATE ingredient
Market Authorisation Date: 08 July, 2019
Treatment: NA
Dosage: SUSPENSION
How can I launch a generic of KATERZIA before its drug patent expiration?
More Information on Dosage
KATERZIA family patents
12. Lazcluze patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE50528 | JANSSEN | NA |
Oct, 2035
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 19, 2029 |
Drugs and Companies using LAZERTINIB MESYLATE ingredient
NCE-1 date: 19 August, 2028
Market Authorisation Date: 19 August, 2024
Treatment: First-line treatment of adults with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 l858r substitution mutations, in combination with amivantam...
Dosage: TABLET
More Information on Dosage
LAZCLUZE family patents
13. Lumify patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12514857 | BAUSCH | Vasoconstriction Compositions And Methods Of Use |
Jul, 2029
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Dec 22, 2020 |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 22 December, 2017
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS
How can I launch a generic of LUMIFY before its drug patent expiration?
More Information on Dosage
LUMIFY family patents
14. Lumify Preservative Free patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12311050 | BAUSCH | Vasoconstriction Compositions And Methods Of Use |
Jul, 2029
(2 years from now) | |
| US12514857 | BAUSCH | Vasoconstriction Compositions And Methods Of Use |
Jul, 2029
(2 years from now) | |
Drugs and Companies using BRIMONIDINE TARTRATE ingredient
Market Authorisation Date: 19 April, 2024
Treatment: Relieves redness of the eye due to minor eye irritations
Dosage: SOLUTION/DROPS
More Information on Dosage
LUMIFY PRESERVATIVE FREE family patents
15. Miebo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12005033 | BAUSCH | Compositions Comprising Mixtures Of Semifluorinated Alkanes |
Sep, 2033
(6 years from now) | |
| US10682315 | BAUSCH | Semifluorinated Compounds And Their Compositions |
Sep, 2036
(9 years from now) | |
| US12128010 | BAUSCH | Semifluorinated Compounds And Their Compositions |
Sep, 2036
(9 years from now) | |
| USRE50060 | BAUSCH | NA |
Jun, 2037
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 18, 2028 |
Drugs and Companies using PERFLUOROHEXYLOCTANE ingredient
NCE-1 date: 19 May, 2027
Market Authorisation Date: 18 May, 2023
Treatment: Treatment of the signs and symptoms of dry eye disease
Dosage: SOLUTION/DROPS
More Information on Dosage
MIEBO family patents
16. Qinlock patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12708617 | DECIPHERA | NA |
Dec, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 15, 2025 |
| Orphan Drug Exclusivity(ODE-298) | May 15, 2027 |
Drugs and Companies using RIPRETINIB ingredient
NCE-1 date: 15 May, 2024
Market Authorisation Date: 15 May, 2020
Treatment: Treatment of gastrointestinal stromal tumor
Dosage: TABLET
More Information on Dosage
QINLOCK family patents
17. Sernivo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12661489 | PRIMUS | NA |
Nov, 2045
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Feb 05, 2019 |
Drugs and Companies using BETAMETHASONE DIPROPIONATE ingredient
Market Authorisation Date: 05 February, 2016
Treatment: Administration of sernivo to hard-to-reach areas of the body with affected skin using a co-packaged telescopic device applicator
Dosage: SPRAY
How can I launch a generic of SERNIVO before its drug patent expiration?
More Information on Dosage
SERNIVO family patents
18. Sofdra patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US12703682 | BOTANIX SB | NA |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jun 20, 2029 |
Drugs and Companies using SOFPIRONIUM BROMIDE ingredient
NCE-1 date: 20 June, 2028
Market Authorisation Date: 18 June, 2024
Treatment: NA
Dosage: GEL, METERED
More Information on Dosage
SOFDRA family patents
19. Symbravo patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12691123 | AXSOME | Pharmaceutical Compositions Comprising Meloxicam |
Apr, 2036
(9 years from now) | |
| US12685736 | AXSOME | NA |
May, 2040
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jan 30, 2028 |
Drugs and Companies using MELOXICAM; RIZATRIPTAN BENZOATE ingredient
Market Authorisation Date: 30 January, 2025
Treatment: Acute treatment of migraine
Dosage: TABLET
How can I launch a generic of SYMBRAVO before its drug patent expiration?
More Information on Dosage
SYMBRAVO family patents
20. Tadliq patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12708626 | CMP DEV | NA |
Dec, 2038
(12 years from now) | |
| US12721849 | CMP DEV | NA |
Dec, 2038
(12 years from now) | |
Drugs and Companies using TADALAFIL ingredient
Market Authorisation Date: 17 June, 2022
Treatment: Tadliq is indicated for the treatment of pulmonary arterial hypertension (pah) (who group 1) to improve exercise ability
Dosage: SUSPENSION
How can I launch a generic of TADLIQ before its drug patent expiration?
More Information on Dosage
TADLIQ family patents
21. Tauklarify patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9808542 | CERVEAU LANTHEUS | Pyrrolo[2,3-C]Pyridines As Imaging Agents For Neurofibrillary |
Jun, 2035
(8 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10022461 | CERVEAU LANTHEUS | Pyrrolo[2,3-C]Pyridines As Imaging Agents For Neurofibrilary Tangles |
Jun, 2035
(8 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 13, 2031 |
Drugs and Companies using FLORQUINITAU F-18 ingredient
NCE-1 date: 13 August, 2030
Market Authorisation Date: 13 August, 2026
Treatment: Tauklarify is a radioactive diagnostic agent for positron emission tomography (pet) imaging of the brain to evaluate for alzheimer’s disease in adult patients with tau neurofibrillary tangle (nft) pat...
Dosage: SOLUTION
More Information on Dosage
TAUKLARIFY family patents
22. Tlando patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12691057 | VERITY | NA |
Apr, 2041
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 28, 2025 |
Drugs and Companies using TESTOSTERONE UNDECANOATE ingredient
Market Authorisation Date: 28 March, 2022
Treatment: Methods of restoring testosterone concentration for conditions associated with deficiency or absence of endogenous testosterone in a male subject
Dosage: CAPSULE
More Information on Dosage
TLANDO family patents
23. Trijardy Xr patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US12678442 (Pediatric) | BOEHRINGER INGELHEIM | Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation |
Oct, 2029
(3 years from now) | |
Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 27 January, 2020
Treatment: NA
Dosage: TABLET, EXTENDED RELEASE
How can I launch a generic of TRIJARDY XR before its drug patent expiration?
More Information on Dosage
TRIJARDY XR family patents
24. Tyvaso Dpi patent expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12679811 | UNITED | Microcrystalline Diketopiperazine Compositions And Methods |
Mar, 2034
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 23, 2025 |
Drugs and Companies using TREPROSTINIL ingredient
Market Authorisation Date: 23 May, 2022
Treatment: Method of treating pulmonary hypertension associated with interstitial lung disease by administering treprostinil or a salt thereof by inhalation using a device
Dosage: POWDER
More Information on Dosage
TYVASO DPI family patents